The United Kingdom and the United States have secured a landmark bilateral deal that will preserve zero duties on UK pharmaceutical products being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to increase expenditure on medicines through the public health system. This move secures that duties on these key exports will be held at nothing for a period of the next three years.
This development is in response to earlier warnings to significantly raise import taxes on patented pharmaceutical imports, with potential rates floated reaching double the cost.
"This agreement between the United Kingdom strengthens the global environment for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," an announcement noted.
Economic Importance
Drugs are one of the UK's biggest export categories to the US, which is easily the largest destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period to the end of last September, the UK sold medicines totaling billions to the US. This value represented a significant portion of British export trade in that timeframe.
"This guarantee safeguards jobs, boosts investment and paves the way for the UK to emerge as a global hub for medical research," the Business and Trade Secretary stated.
Key UK Commitments
The pact entails several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase total public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, rebates topped twenty percent.
Broader Context
The pact follows a long-running dispute between the drug companies and the UK government over spending levels and NHS adoption.
This friction were exacerbated by arguments that American customers were paying several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while major funding commitments have been pledged toward American operations.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the past decade.
